Chunli Medical's stock price surged 5.74% during intraday trading on Tuesday, following the release of its robust financial results for the year ended 2025 and the announcement of a final dividend.

The company reported a 29.8% year-on-year increase in revenue to RMB1.05 billion, with net profit attributable to shareholders more than doubling to RMB272.54 million, representing a 118.7% surge. The strong performance was driven by higher sales of orthopedic implants, accelerating overseas expansion, and improved cost controls that lifted operating margins.

Concurrently, the board declared a final ordinary cash dividend of RMB 1.50 per 10 shares for the 2025 financial year, subject to shareholder approval at the upcoming annual general meeting. The combination of exceptional earnings growth and shareholder returns through dividends appears to have driven positive investor sentiment.